
MitoRx Therapeutics
Biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
investor investor investor investor investor investor | €0.0 | round | |
* | £3.0m | Seed | |
Total Funding | 000k |
Related Content
MitoRx Therapeutics is a pioneering biotech company focused on developing first-in-class therapeutics that target mitochondrial dysfunction. The company operates in the healthcare and biotechnology market, specifically addressing rare diseases such as muscular dystrophy and neurodegenerative disorders. MitoRx Therapeutics serves patients suffering from these debilitating conditions, offering them hope through innovative treatments that reverse mitochondrial dysfunction and arrest disease progression. The company's business model revolves around research and development, clinical trials, and eventual commercialization of their therapeutic solutions. Revenue is generated through partnerships, licensing agreements, and direct sales of their approved drugs. The leadership team boasts extensive experience in biotech, with backgrounds in business development, intellectual property, and clinical program management.
Keywords: mitochondrial dysfunction, muscular dystrophy, neurodegeneration, biotech, therapeutics, rare diseases, clinical trials, drug development, healthcare, innovation.